Alexion Pharmaceuticals (ALXN) - 22 Year Stock Price History

Historical daily stock prices for Alexion Pharmaceuticals since 1996 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Alexion Pharmaceuticals (ALXN) as of June 21, 2018 is 125.81.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $27.706B $3.551B
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).